Overview

Study of NM8074 in Patients With aHUS

Status:
Not yet recruiting

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.

Phase:

Phase 2

Details

Lead Sponsor:

NovelMed Therapeutics